The federal government announced the closure of all utility stores across the country, citing persistent financial losses despite multiple efforts to revive the organization.
Addressing a press conference in Islamabad on Sunday, Minister for Parliamentary Affairs Tariq Fazal Chaudhry said the decision was taken on the prime minister’s directives, and the stores will be shut down from August 31. Senior officials of the Utility Stores Corporation (USC) were also present at the briefing.
“The Utility Stores Corporation has played a significant role in the national economy since its establishment in 1971,” the minister said. “Despite continuous efforts, we failed to reduce the losses of the corporation, and therefore, it had to be closed down,” he added.
The minister revealed that USC currently employs 11,614 workers, who will receive a Rs28 billion severance package. “The rights of employees have been fully safeguarded, and even contractual staff will be compensated,” he added.
The minister further announced that all USC assets nationwide will be auctioned, ensuring transparency in the process.
The day three of the Hero Asia Cup in Rajgir, Bihar 2025 delivered another thrilling double-header of Pool A action, with fans treated to a goal avalanche from China and a nail-biting victory for hosts India in front of a roaring Rajgir crowd.
China displayed ruthlessness against Kazakhstan in their match. They flexed their attacking muscle with a commanding 13–1 win over Kazakhstan in the day’s opening match.
From the first whistle, China looked sharp, combining pace, precision, and relentless finishing to rack up a dominant scoreline. Kazakhstan managed a consolation strike but were left overwhelmed by China’s all-round superiority.
In the second match of the day, hosts India edged past Japan in a thrillers.
This was their second win in the event with a very close margin against thier opponents.
The marquee clash of the day had fans on the edge of their seats as India edged past Japan 3–2 in a pulsating contest.
Both teams showcased end-to-end hockey, tactical sharpness, and moments of brilliance, but it was the hosts who held their nerve in the decisive moments. With the crowd in full voice, India sealed a memorable win that could prove crucial in the Pool A standings.
2 Matches
19 Goals scored
China’s goal storm and India’s dramatic triumph headline the day
Tomorrow’s Schedule – Monday, 1 September 2025:
Match 09: Bangladesh vs Korea (Pool B)
Match 10: Malaysia vs Chinese Taipei (Pool B)
Match 11: China vs Japan (Pool A)
Match 12: India vs Kazakhstan (Pool A)
With four high-stakes encounters lined up tomorrow, fans can expect another action-packed day at the Hero Asia Cup Rajgir, Bihar 2025.
Neoadjuvant immunotherapy plus chemotherapy appears to be effective in patients with limited-stage small cell lung cancer (SCLC), a new report indicates. The study was published in Thoracic Cancer.1
SCLC makes up only about 10-15% of lung cancer cases, the authors explained. Limited-stage cases of SCLC (LS-SCLC) make up a minority of new SCLC cases, they noted, as most patients are not diagnosed until their disease has reached extensive-stage status.
PD-1 inhibitors have shown considerable promise for patients with extensive-stage SCLC. And just last year, the ADRIATIC study (NCT03703297) suggested that the anti-PD-1 therapy durvalumab (Imfinzi; AstraZeneca) was effective as a consolidation therapy for patients with stable LS-SCLC post-concurrent chemoradiotherapy, the investigators noted.2 That study was an important milestone demonstrating the efficacy of PD-1/PD-L1 inhibitors in a LS-SCLC setting, they explained.1
The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer – stock.adobe
In the new report, the investigators wanted to expand the knowledge base around the role of neoadjuvant immunotherapy in treating patients with LS-SCLC. To do so, they searched for existing research that included clinical outcomes and safety data for the treatment regimen. After exclusions, they analyzed a total of 6 studies with a collective patient population of 114. They then completed a meta-analysis, which showed that the pooled rates of pathological complete response (pCR) were 35% (95% CI, 14%-56%) and the major pathological response (MPR) rate was 49% (95% CI, 18%-80%).
“Notably, patients who underwent more than two neoadjuvant cycles exhibited a higher rate of pCR and MPR compared to those who received only two cycles of neoadjuvant therapy,” the authors said.
The investigators said most (95%) patients achieved R0 surgical resection (95% CI, 85%-100%). The rate of treatment-related serious adverse events was 44% (95% CI, 13%-76%). None of the studies reported patient deaths during the perioperative period.
“The safety outcomes demonstrated acceptable toxicity in neoadjuvant immunotherapy for SCLC,” the investigators wrote.
The combination of immunotherapy and chemotherapy has become a first-line treatment modality in patients with extensive-stage SCLC, they added.
“These findings further suggest that the application of immunotherapy combined with chemotherapy in the perioperative setting of LS-SCLC may have significant implications,” they said. This strategy might be able to reduce tumor burden, provide additional treatment opportunities for patients, and ultimately improve treatment outcomes and survival.
The authors noted that 81% of participants included in the 6 studies had stage III SCLC, suggesting that neoadjuvant immunotherapy could be a meaningful treatment option for such patients. They added that the survival benefits of the therapy were similar in patients with stage IIIA and IIIB disease.
The investigators listed several limitations to their findings. They said the number of studies and patients included in the analysis may be too small to generalize to a broad population. In addition, they noted that all of the studies included were from China, highlighting the need for similar trials in more diverse populations. They added that, given the high number of patients with stage III SCLC in the trials, their findings might be most helpful for stage III patients.
Going forward, the authors cautioned that several challenges will need to be addressed before neoadjuvant immunotherapy can become a standard treatment option in SCLC. Among the challenges is the need to gain a better understanding of how neoadjuvant immunotherapy works in patients with locally advanced SCLC. They said they hope their findings will help guide ongoing and future clinical trials to help solve those remaining challenges.
References
1. Ge F, Lin G, Huo Z, Wang Z, Sun N, He J. A comprehensive study on clinical outcomes and safety of neoadjuvant immunotherapy combined with chemotherapy in limited-stage small cell lung cancer. Thorac Cancer. 2025;16(15):e70125. doi:10.1111/1759-7714.70125
2. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-1327. doi:10.1056/NEJMoa2404873
A team of researchers at MIT looking for a way to improve the safety and durability of nuclear reactors has accidentally discovered a new technique that could boost the performance of computer chips. The team’s work was only designed to study how materials corrode and crack in the harsh environment found within a nuclear reactor.
The research — published in the journal Scripta Materialia — involved the use of a powerful, focused X-ray beam to mimic the intense radiation present inside a nuclear reactor. While conducting experiments with nickel — a common alloy component in advanced nuclear reactors — the researchers made an unexpected finding. They discovered they could also use the X-ray beam to precisely “tune” the strain in the material’s crystal structure.
This could have a major impact in the development of microelectronics. Engineers working in the sector of semiconductor manufacturing employ strain engineering — a technique used to introduce and modify strain in materials to improve optical and electrical performance. This new discovery provides a novel strain engineering technique.
With our technique, engineers can use X-rays to tune the strain in microelectronics while they are manufacturing them. While this was not our goal with these experiments, it is like getting two results for the price of one. — Ericmoore Jossou, senior author of a study.
The research was also successful with regard to its original aim. The team successfully developed a method for real-time 3D monitoring of material failure in a simulated nuclear reactor environment. The team also found that prolonged exposure to the X-ray relaxed the internal strain of the material, allowing for accurate 3D reconstruction of the crystal as it was being stressed. A feat Jossou says no one has achieved before.
I have always been fascinated by technology and digital devices my entire life and even got addicted to it. I have always marveled at the intricacy of even the simplest digital devices and systems around us. I have been writing and publishing articles online for about 6 years now, just about a year ago, I found myself lost in the marvel of smartphones and laptops we have in our hands every day. I developed a passion for learning about new devices and technologies that come with them and at some point, I asked myself, “Why not get into writing tech articles?” It is useless to say I followed up the idea — it is evident. I am an open-minded individual who derives an infinite amount of joy from researching and discovering new information, I believe there is so much to learn and such a short life to live, so I put my time to good use — learning new things. I am a ‘bookworm’ of the internet and digital devices. When I am not writing, you will find me on my devices still, I do explore and admire the beauty of nature and creatures. I am a fast learner and quickly adapt to changes, always looking forward to new adventures.
The official EuroBasket app
Download Now
LIMASSOL (Cyprus) – Giannis Antetokounmpo guided Greece to a third win in three games at FIBA EuroBasket 2025 with 27 points – his eighth consecutive game with 25+ points at EuroBasket.
Only one other player in EuroBasket history has a better streak: Greek legend Nikos Galis with 19.
Player |
Team |
25+ PTS streak |
---|---|---|
Nikos Galis |
Greece |
19 |
Giannis Antetokounmpo |
Greece |
8 |
Radivoj Korac |
Yugoslavia |
7 |
Doron Jamchi |
Israel |
6 |
Dariusz Zelig |
Poland |
5 |
Aleksandar Vezenkov |
Bulgaria |
5 |
Lauri Markkanen |
Finland |
5 |
Alexey Shved |
Russia |
4 |
Drazen Petrovic |
Yugoslavia |
4 |
Jorgen Hansson |
Sweden |
4 |
Pau Gasol |
Spain |
4 |
Giannis is leading Greece’s charge towards what they hope will be a first title since 2005 with averages of 29.0 points, 7.5 rebounds and 3.0 assists per game through two outings.
“I am very blessed and grateful that we have Giannis here,” said Greece head coach Vasileios Spanoulis. “He always has the right mindset. He’s very humble. He plays for his country and loves his teammates. Like all the guys, he’s trying to win.”
And, Giannis can continue to cement his legacy among the all-time greats of Greek basketball, with the chance of perhaps breaking one of Galis’ records.
Giannis made his EuroBasket debut in 2015, but would start of his streak of 25+ points in game at the last edition in 2022 – having missed out in 2017.
Date |
Round |
Opponent |
Points |
---|---|---|---|
31/08/2025 |
Group Phase |
Georgia |
27 |
28/08/2025 |
Group Phase |
Italy |
31 |
13/09/2022 |
Quarter-Finals |
Germany |
31 |
11/09/2022 |
Round of 16 |
Czechia |
27 |
08/09/2022 |
Group Phase |
Estonia |
25 |
06/09/2022 |
Group Phase |
Ukraine |
41 |
03/09/2022 |
Group Phase |
Italy |
25 |
02/09/2022 |
Group Phase |
Croatia |
27 |
How long would it take? Well, with a maximum of six more games in this edition should Greece make it to the Final, Giannis could move to 14 straight games of 25+ points.
That means he could actually tie the record in the final game of Group Phase action at FIBA EuroBasket 2029 – which will be co-hosted by Greece.
FIBA
The Lenovo Yoga Tab Plus may not boast any groundbreaking features, or even the latest silicon, but it sure does deliver as a well-rounded productivity and entertainment machine at a fair asking price. Thanks to an ongoing sale on Lenovo, the Yoga Tab Plus can now be purchased at a pretty lucrative all-time low price of just $444.59, courtesy of a $325 discount as well as a couple of coupons.
The Yoga Tab Plus is a pretty large tablet at 12.7-inches, featuring a resolution of 2944 x 1840 which allows for a decently sharp pixel density of 273 PPI. The IPS panel refreshes at 144 Hz, which will surely elate gamers and chronic scrollers. However, the benefits of an OLED panel are obviously missing, such as true blacks, instant response times, and impressive color accuracy. Our review of the tablet noted a 73% coverage of the DCI-P3 color space, which is passable, but nothing quite to phone home about.
That said, the majority of folks with casual gaming and content consumption requirements will hardly ever find any room for complaint with the Lenovo Yoga Tab Plus, considering the affordable pricing. The same is reflected in the tablet’s performance, which is decent, courtesy of the Snapdragon 8 Gen 3 SoC, but can’t really keep up with higher-end chips. Lenovo offers four years of OS upgrades, which is quite disappointing since Samsung offers an additional three years.
Of course, the Yoga Tab Plus is a productivity-focused machine, like many other offerings from Lenovo, and ships with a keyboard with a touchpad, a stylus, as well as a cover with a kickstand. The list of accessories offered is undoubtedly generous, which we were pretty happy with in our detailed review. Other notable features of the tablet are as follows:
In order to take full advantage of the ongoing sale, potential customers are requested to use the coupons “EXTRAFIVE” and “LENOVOLIVE10” during checkout.
As a true tech nerd and lover of all things Apple, I love reading, researching and writing about the latest advancements from the Cupertino giant. My fascination with Apple’s design philosophy, commitment to user satisfaction , and dedication towards pushing the boundaries of consumer technology keeps me eagerly anticipating what they’ll unveil next.
This week a new Ubuntu X1E Concept ISO was published for Ubuntu 25.04 ARM64 with the latest Qualcomm Snapdragon X Elite/Plus laptop optimizations. With this new ISO the Linux 6.17 kernel is now leveraged for the latest upstream kernel bits. Additionally, the new X1E ISO is finally working again on the Acer Swifth 14 AI laptop that I have used for my Snapdragon X Elite Linux testing.
The plucky-desktop-arm64+x1e-20250827.iso image is now available for those wanting the latest Ubuntu Linux experience catering to the Snapdragon X Elite laptops. The ISO is available for download from this directory.
Excitingly, when trying it out on the Acer Swift 14 AI laptop I’ve used for the Linux testing, this new ISO is working properly on that laptop without any Device Tree issues or boot issues post-install. It’s been months since this “supported” laptop has been working nicely with the new Ubuntu X1E Concept images – I think the last time was when installing the Ubuntu 24.10 X1E Concept ISO and then upgrading manually to 25.04 packages at the time.
This new concept image is working out fine on the Acer Swift 14 AI. Also making this new ISO image more exciting is that it has transitioned to using the Linux 6.17 development kernel for the very latest upstream kernel support for the Qualcomm Snapdragon X hardware.
Post-install you still need to install qcom-firmware-extract and run it for those laptops (most models out there, unfortunately) without any upstream linux-firmware support by extracting the firmware files from your Windows on ARM partition.
In any event I am now working on some fresh Ubuntu X Elite benchmarks now that I have a working laptop. Stay tuned for a fresh comparison against AMD Ryzen and Intel Core laptops.